Acute Effect of Photobiomodulation on Quadriceps Muscle Strength in Patients With Chronic Kidney Failure on Hemodialysis

Renal Insufficiency, Chronic Clinical Trial

Official title:

Acute Effect of Photobiomodulation Therapy on Quadriceps Muscle Strength in Patients With Chronic Kidney Failure on Hemodialysis: a Crossover Randomized Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05881772
• Other study ID #: Laser_HD
• Status: Completed
• Phase: N/A
• Start date: June 1, 2023
• Est. completion date: August 1, 2023

Study information

• Verified date: November 2023
• Source: Federal University of Health Science of Porto Alegre
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Chronic kidney disease (CKD) consists of kidney damage and progressive and irreversible loss of kidney function. The aim of this study is to evaluate the acute effect of different doses of photobiomodulation therapy on quadriceps isometric muscle strength, pain and muscle fatigue of lower limbs and to establish the ideal dose for patients with CKD on hemodialysis. Patients will be submitted to application of photobiomodulation therapy in the quadriceps muscle. Immediately after, the maximum isometric strength test of the quadriceps will be performed.

Description:

Chronic kidney disease (CKD) consists of kidney damage and progressive and irreversible loss of kidney function. In the most advanced stage of the disease the patients require hemodialysis (HD) and present alterations such as: sarcopenia, cardiovascular disorders, increased systemic inflammation, muscle weakness and fatigue. These factors negatively affect the individual's functionality, impacting the increase in hospitalization and mortality rates. Photobiomodulation (FBM) has shown positive results in different populations on improving performance during exercise, reducing fatigue and markers of muscle damage. The aim of this study is to evaluate the acute effect of FBM therapy on quadriceps muscle strength, pain and muscle fatigue in patients with CKD on HD and to establish the ideal therapeutic dose. Patients will be submitted to application of four applications with different doses of FBM (30J, 60J, 90J and placebo) in the quadriceps muscle, in random order and one week interval between them for washout. Patients and evaluators will be blinded to the intervention protocol. The following assessments will be performed prior to FBM: subjective perception of exertion (by modified Borg scale), muscle fatigue (by analysis of blood lactate) and pain perception (by numeric pain scale). After the FBM application, the maximum isometric strength test of the quadriceps will be performed by dynamometry. Immediately after performing the strength test, all assessments will be repeated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: August 1, 2023
• Est. primary completion date: July 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients with CKD on HD for a period = 3 months;
• Age between 18-80 years old;
• Patients of both sexes;
• Dialysis with a weekly frequency of 3 times/week;
• Adequate urea clearance rate (Kt/V = 1.2 or URR =65%).

Exclusion Criteria:

• Cognitive dysfunction that prevents the performance of the assessments, as well as inability to understand and sign the informed consent form;
• Epidermal lesions at the site of application of photobiomodulation therapy;
• Patients with recent stroke sequelae (three months);
• Recent acute myocardial infarction (two months);
• Uncontrolled hypertension (SBP>230 mmHg and DBP>120 mmHg);
• HF grade IV according to the New York Heart Association or decompensated;
• Unstable angina;
• Peripheral vascular changes in lower limbs such as deep venous thrombosis;
• Disabling osteoarticular or musculoskeletal disease;
• Uncontrolled diabetes (blood glucose > 300mg/dL);
• Febrile state and/or infectious disease;
• Systemic lupus erythematosus;
• Patients undergoing cancer treatment.

Related Conditions & MeSH terms

• Kidney Failure, Chronic
• Renal Dialysis
• Renal Insufficiency
• Renal Insufficiency, Chronic

Intervention

Other:
• Photobiomodulation
It will be applied a dose of laser radiation through a cluster with four diodes, wavelength of 830 nm and power of 800mW (200mW/diode), HTM® (model Fluence MAXX, São Paulo, Brazil). For application, the patient will be positioned in a sitting position and the treatment will be performed with the fixed probe in contact with the skin at an angle of 90º, using the continuous emission mode. The therapy will be applied to the quadriceps muscle, bilaterally.

Locations

Country	Name	City	State
Brazil	Santa Casa de Misericórdia de Porto Alegre	Porto Alegre	Rio Grande Do Sul

Sponsors (1)

Lead Sponsor	Collaborator
Federal University of Health Science of Porto Alegre

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximal isometric muscle strength of the quadriceps	Maximal isometric muscle strength of the quadriceps will be assessed by dynamometry.	Immediately after the aplication of photobiomodulation therapy.
Secondary	Muscle pain of lower limbs	Muscle pain of lower limbs will be assessed by the numeric pain scale (NPS). Zero means no pain and 10 maximum pain.	Baseline and immediately after the dynamometry.
Secondary	Fatigue	Fatigue of lower limbs by the modified Borg subjective perceived exertion scale Modified Borg (Borg Scale). Zero means no effort or fatigue and 10 maximum effort or fatigue.	Baseline and immediately after the dynamometry.
Secondary	Fatigue	Fatigue of lower limbs by blood lactate dosage.	Baseline, immediately after dynamometry, at 3 and 6 minutes.